← Browse by Condition
Medical Condition
interstitial lung disease ild
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2
Pulmonary clinical trials span chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and rare ILDs β€” each with distinct pathophysiology and treatment targets. IPF research is particularly active, building on pirfenidone and nintedanib to identify anti-fibrotic combinations that slow disease more effectively.
Trials include inhaled triple combinations for COPD (LABA/LAMA/ICS), treprostinil subcutaneous for PAH, PDE4B inhibitors, anti-CCL2 antibodies for fibrosis, and aerosol gene therapy for CF (CFTR modulators plus mRNA). FEV1, 6-minute walk distance, and lung function decline remain core endpoints with patient-reported outcomes gaining weight.
Frequently Asked Questions — interstitial lung disease ild Clinical Trials
How many clinical trials are currently recruiting for interstitial lung disease ild?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for interstitial lung disease ild, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for interstitial lung disease ild?
interstitial lung disease ild research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a interstitial lung disease ild clinical trial?
Eligibility criteria for interstitial lung disease ild trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07500818
Recruiting
Enrollment
30 pts
Location
Switzerland
Sponsor
University of Zurich
NCT06655090
Recruiting
Enrollment
10,000 pts
Location
China
Sponsor
Dai Huaping
NCT07173348
Recruiting
Enrollment
82 pts
Location
Switzerland
Sponsor
University Hospital, Geneva
NCT07333183 Phase 2
Recruiting
Enrollment
20 pts
Location
United States
Sponsor
Pulmovant, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology